Related Experiment Videos
Fluticasone versus salmeterol/low-dose fluticasone for long-term asthma control
Catherine A Heyneman1, Rachel Crafts, Jerry Holland
1Idaho Drug Information Service, Pocatello, USA. cathy@otc.isu.edu
The Annals of Pharmacotherapy
|November 28, 2002
Summary
Adding salmeterol to low-dose fluticasone propionate significantly improves long-term asthma control compared to increasing fluticasone propionate dosage alone. This combination therapy offers superior symptom management and lung function for persistent asthma patients.
Area of Science:
- Pulmonology
- Pharmacology
- Clinical Medicine
Background:
- Current asthma guidelines recommend inhaled corticosteroids (ICS) or ICS with a long-acting bronchodilator for long-term control.
- Previous research suggests combination therapy often outperforms dose escalation of ICS alone.
Purpose of the Study:
- To compare the clinical effectiveness of increasing fluticasone propionate (FP) dose versus adding salmeterol (SAL) to low-dose FP for managing persistent asthma.
- To evaluate which treatment strategy offers superior long-term asthma control.
Main Methods:
- A literature search was conducted using MEDLINE (1966-October 2002) with keywords: asthma, inhalation, corticosteroid, beta-adrenergic agonist, and combination drug therapy.
- Four controlled clinical trials comparing FP monotherapy with SAL/low-dose FP were analyzed.
Main Results:
- The addition of salmeterol to low-dose fluticasone propionate demonstrated superior outcomes compared to increasing the fluticasone propionate dose.
- Improvements were noted in spirometry data, reduced need for rescue albuterol, and better symptom scores.
Conclusions:
- Combining salmeterol with low-dose fluticasone propionate provides enhanced asthma control.
- This combination therapy is more effective than escalating fluticasone propionate dosage alone, evidenced by improved FEV1, PEF, and symptom control.